PDE5 inhibitors, like sildenafil, have demonstrated potential anti-tumor effects in preclinical studies, suggesting that targeting PDE5 may be a promising strategy for cancer therapy [13,14,15]. The gene discussed is PDE5A; the disease is cancer.